The role of T cells in osteoporosis, an update

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 6, 2009, Pages 544-552

  Zhao, Wen ^a   Liu, Yuying ^b   Cahill, Catherine M ^c   Yang, Wenlu ^d,e   Rogers, Jack T ^c   Huang, Xudong ^c,d  

^a Beijing Aerospace General Hospital   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e SHANGHAI MARITIME UNIVERSITY   (China)

Author keywords

Chemokine; Cytokine; Osteoclast; Osteoclastogenesis; Osteoporosis; T cells

Indexed keywords

EID: 67650249715     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Osteoporosis. National Institutes of Health Consensus Development Conference Statement. Natl Inst Health Consens Dev Conf Consens Statement 1984;5:6
2. Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW and Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-1010.
3. Tilg H, Moschen AR, Kaser A, Pines A and Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008;57: 684-694.
4. Marom R, Shur I, Solomon R and Benayahu D. Characterization of adhesion and differentiation markers of osteogenic marrow stromal cells. J Cell Physiol 2005;202: 41-48.
5. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ and Suda T. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990;87:7260-7264.
6. Kurihara N, Chenu C, Miller M, Civin C and Roodman GD. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 1990;126: 2733-2741.
7. Kodama H, Nose M, Niida S and Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991;173:1291-1294.
8. Jacquin C, Gran DE, Lee SK, Lorenzo JA and Aguila HL. Identification of multiple osteoclast precursor populations in murine bone marrow. J Bone Miner Res 2006;21: 67-77.
9. Teitelbaum SL. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 2004; 101:16711-16712.
10. Rifas L and Arackal S. T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthritis Rheum 2003;48:993-1001.
11. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457-475.
12. Weitzmann MN and Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006;116:1186-1194.
13. Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ and Gillespie MT. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003;18:984-993.
14. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K and Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.
15. Di Rosa F and Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005;26:360-366.
16. Cassese G, Parretta E, Pisapia L, Santoni A, Guardiola J and Di Rosa F. Bone marrow CD8 cells down-modulate membrane IL-7Ralpha expression and exhibit increased STAT-5 and p38 MAPK phosphorylation in the organ environment. Blood 2007;110:1960-1969.
17. Parretta E, Cassese G, Santoni A, Guardiola J, Vecchio A and Di Rosa F. Kinetics of in vivo proliferation and death of memory and naive CD8 T cells: parameter estimation based on 5-bromo-2′-deoxyuridine incorporation in spleen, lymph nodes, and bone marrow. J Immunol 2008;180:7230-7239.
18. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hammerling GJ, Kyewski B, Hamann A, Umansky V and Schirrmacher V. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003;9:1151-1157.
19. Mazo IB, Honczarenko M, Leung H, Cavanagh LL, Bonasio R, Weninger W, Engelke K, Xia L, McEver RP, Koni PA, Silberstein LE and von Andrian UH. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 2005;22:259-270.
20. Paiardini M, Cervasi B, Engram JC, Gordon SN, Klatt NR, Muthukumar A, Else J, Mittler RS, Staprans SI, Sodora DL and Silvestri G. Bone marrow-based homeostatic proliferation of mature T cells in nonhuman primates: implications for AIDS pathogenesis. Blood 2009;113:612-621.
21. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ and Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402: 304-309.
22. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J and Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229-1237.
23. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G and Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98: 13960-13965.
24. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O and Pacifici R. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100:10405-10410.
25. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP and Isaia G. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 2008; 43: 92-100.
26. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ and Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.
27. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM and Kwon BS. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001;31:2179-2188.
28. John V, Hock JM, Short LL, Glasebrook AL and Galvin RJ. A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology 1996;137:2457-2463.
29. Josien R, Wong BR, Li HL, Steinman RM and Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-2568.
30. Grcevic D, Lee SK, Marusic A and Lorenzo JA. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 2000; 165:4231-4238.
31. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP and Weitzmann MN. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109:3839-3848.
32. Wyzga N, Varghese S, Wikel S, Canalis E and Sylvester FA. Effects of activated T cells on osteoclastogenesis depend on how they are activated. Bone 2004;35:614-620.
33. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304.
34. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508.
35. Anandarajah AP. Role of RANKL in bone diseases. Trends Endocrinol Metab 2009; 20:88-94.
36. Leibbrandt A and Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008;1143:123-150.
37. Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S and Inoue J. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005;24:790-799.
38. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K, Yamaguchi A, Takai T, Kodama T, Chatila TA, Bito H and Takayanagi H. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med 2006;12:1410-1416.
39. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR and Glimcher LH. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008;118:3775-3789.
40. Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y and Lee SY. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 2009;119: 813-825.
41. Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, Iwakura Y, Suda T and Matsuo K. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 2009 [Epub ahead of print]
42. Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J and Sun SC. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008;118:1858-1866.
43. Kim HJ, Zhang K, Zhang L, Ross FP, Teitelbaum SL and Faccio R. The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2009;106:2325-2330.
44. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R and Novack DV. RelA/ p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008;118:2088-2097.
45. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-371.
46. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE and Lipsky PE. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-1030.
47. Wei S, Kitaura H, Zhou P, Ross FP and Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115: 282-290.
48. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP and Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-3427.
49. Ochi S, Shinohara M, Sato K, Gober HJ, Koga T, Kodama T, Takai T, Miyasaka N and Takayanagi H. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci USA 2007; 104: 11394-11399.
50. Ukai T, Yumoto H, Gibson FC, 3rd and Genco CA. Macrophage-elicited osteoclastogenesis in response to bacterial stimulation requires Toll-like receptor 2-dependent tumor necrosis factor-alpha production. Infect Immun 2008;76:812-819.
51. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M, Yamaguchi A, Deprez P, Mollat P, Murali R, Ohya K, Horne WC and Baron R. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 2006;116:1525-1534.
52. Lorenzo J, Horowitz M and Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29: 403-440.
53. Madyastha PR, Yang S, Ries WL and Key LL, Jr. IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. J Interferon Cytokine Res 2000;20:645-652.
54. Huang W, O'Keefe RJ and Schwarz EM. Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther 2003;5: R49-59.
55. Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, Kobashigawa T, Togari A and Kamatani N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 2005;35:3353-3363.
56. Moriyama H, Ukai T and Hara Y. Interferon-gamma production changes in parallel with bacterial lipopolysaccharide induced bone resorption in mice: an immunohistometrical study. Calcif Tissue Int 2002;71:53-58.
57. Teng YT, Mahamed D and Singh B. Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo. Infect Immun 2005;73:3453-3461.
58. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN and Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007;117:122-132.
59. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R and Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54: 1122-1131.
60. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA and van den Berg WB. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005;167: 141-149.
61. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y and Katz Y. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009;46:1854-1859.
62. Nakae S, Saijo S, Horai R, Sudo K, Mori S and Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100:5986-5990.
63. Nakae S, Nambu A, Sudo K and Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-6177.
64. Lubberts E, Schwarzenberger P, Huang W, Schurr JR, Peschon JJ, van den Berg WB and Kolls JK. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005;175:3360-3368.
65. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L and Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-970.
66. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P and Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008;58: 875-887.
67. Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Kolls JK, Di Padova FE, Joosten LA and van den Berg WB. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006; 176: 6262-6269.
68. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, Kirkham BW and Taams LS. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci USA 2009;106:6232-6237.
69. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE and Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-2497.
70. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ and Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008;105:14993-14998.
71. Weitzmann MN and Pacifici R. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 2006; 1068: 256-274.
72. Lee SH, Kim TS, Choi Y and Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep 2008;41:495-510.